CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D000075902: Clinical Deterioration NIH

(Synonyms: Clinical Deterioration)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug325 CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test Wiki 1.00
drug1292 convalescent plasma application to SARS-CoV-2 infected patients Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.11
D007239 Infection NIH 0.07
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19)

This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression. In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma. Only patients with moderate to severe disease at risk for transfer to intensive care unit or patients at the intensive care unit with limited treatment options will be treated.

NCT04389944 Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection) Other: convalescent plasma application to SARS-CoV-2 infected patients
MeSH:Communicable Diseases Infection Coronavirus Infections Clinical Deterioration

Primary Outcomes

Description: Serious adverse events during the study period include transfusion reaction (fever, rash), transfusion related acute lung injury (TRAU) , transfusion associated circulatory overload (TACO) , transfusion related infection

Measure: Serious adverse events in convalescent plasma treated patients

Time: From baseline (enrolment) to 24 hours follow-up

Description: Change in SARS-CoV2 quantitative in nasopharyngeal swab

Measure: Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients

Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28

Description: Transfer to ICU

Measure: Transfer to ICU

Time: at Baseline (admission to Covid-ward) until day 28

Description: in-hospital death

Measure: in-hospital death

Time: at Baseline (admission to Covid-ward) until day 28

Description: Change in SARS-CoV2 quantitative in plasma

Measure: Virologic clearance in plasma of convalescent plasma treated patients

Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28

Secondary Outcomes

Description: Duration of hospitalisation

Measure: Time to discharge from hospital after enrolment

Time: at Baseline (admission to Covid-ward) until discharge (approx. 28 days)

Description: Rise of SARS-CoV-2 antibody titers (on day 1, 7, 14 and 28)

Measure: Humoral immune response

Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28


HPO Nodes